Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 180, 109036
Abstract
No abstract availableKeywords
Funding Information
- National Heart Foundation of Australia
This publication has 21 references indexed in Scilit:
- Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME TrialAmerican Journal of Kidney Diseases, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic ControlCirculation, 2018
- Impact of the Canadian Diabetes Association guideline dissemination strategy on clinician knowledge and behaviour change outcomesDiabetes Research and Clinical Practice, 2018
- The future of continuing medical education: the roles of medical professional societies and the health care industryEuropean Heart Journal, 2018
- Drug promotion practices: A reviewBritish Journal of Clinical Pharmacology, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Barriers to effective management of type 2 diabetes in primary care: qualitative systematic reviewBritish Journal of General Practice, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015